Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Variant reclassification following hereditary cancer genetic testing is common, according to a study published by…
From - Diagnostic Testing & Emerging Technologies
Point-of-care (POC) testing that could simultaneously identify multiple sexually transmitted infections (STIs) could be a valuable addition to…
From - Diagnostic Testing & Emerging Technologies
Current hepatitis C virus (HCV) screening strategies may not be adequate in the face of the opioid epidemic…
From - Diagnostic Testing & Emerging Technologies
What will the laboratory of the future look like?
Attendees at G2's 36th annual Lab Institute (Oct. 24-26; Washington, D.C.) got a glimpse in the keynote…
From - Diagnostic Testing & Emerging Technologies
Labs need to take a more prominent role in the broader health care ecosystem—from being a recognized member of patient care teams to being a leading player in…